1. Home
  2. DINO vs BBIO Comparison

DINO vs BBIO Comparison

Compare DINO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HF Sinclair Corporation

DINO

HF Sinclair Corporation

HOLD

Current Price

$113.63

Market Cap

12.9B

Sector

Energy

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$71.13

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DINO
BBIO
Founded
1947
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
13.3B
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
DINO
BBIO
Price
$113.63
$71.13
Analyst Decision
Hold
Strong Buy
Analyst Count
17
23
Target Price
★ $123.94
$107.81
AVG Volume (30 Days)
2.0M
★ 2.4M
Earning Date
10-28-2026
10-29-2026
Dividend Yield
★ 1.84%
N/A
EPS Growth
★ 238.46
N/A
EPS
★ 8.48
N/A
Revenue
N/A
★ $502,076,000.00
Revenue This Year
$31.33
$107.07
Revenue Next Year
N/A
$60.44
P/E Ratio
$13.47
★ N/A
Revenue Growth
N/A
★ 126.26
52 Week Low
$45.71
$60.23
52 Week High
$129.37
$93.42

Technical Indicators

Market Signals
Indicator
DINO
BBIO
Relative Strength Index (RSI) 43.24 59.88
Support Level $103.00 $63.16
Resistance Level $118.39 $71.74
Average True Range (ATR) 5.26 1.89
MACD -1.68 0.79
Stochastic Oscillator 20.30 96.13

Price Performance

Historical Comparison
DINO
BBIO

About DINO HF Sinclair Corporation

HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: